RxDoctor Payments Data

Breanne McGhee

Optometrist · New Orleans, LANPI 1386996619

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,925 of the $14,326 with a category attached, or 62.3%. AbbVie accounts for 87.1% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $11,995, more than ten times the $59 reported in 2019. Among optometrist clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,326in general payments, 2019–2025

Across 41 payments — averaging $349.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$12K
  • Immunogen, Inc.$829
  • Dompe US, Inc.$294
  • Bausch & Lomb Americas Inc.$147
  • Biotissue Holdings Inc.$130
  • Alcon$129
  • plus $325 from 6 others

What the payments were for

  • Consulting fees$1,3249%
  • Speaking & faculty fees$8,92562%
  • Travel & lodging$2,34616%
  • Food & beverage$1,71312%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,326 in reported general payments places this provider in the 95th percentile of 500 optometrist providers in Louisiana.

See all optometrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$18,402
Medicare patients
199
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine11$9,556
Prednisolone Acetate155$5,176
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha61$811
Latanoprost73$603
Dorzolamide Hcl11$301
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat12$270
ErythromycinErythromycin Base21$249
Timolol Maleate12$229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$12,472$9,55611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 500 optometrist providers in Louisiana.

Other optometrist in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →